InSightec ExAblate Panel To Consider International Uterine Fibroid Data
This article was originally published in The Gray Sheet
Executive Summary
InSightec's PMA for non-invasive ExAblate 2000 treatment of uterine fibroids will be reviewed by FDA's Obstetrics & Gynecology Devices Panel June 3
You may also be interested in...
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
InSightec Panel Acquiesces Despite Efficacy, Control Group Concerns
Labeling for InSightec's ExAblate 2000 non-invasive uterine fibroid treatment should describe "mitigations" to minimize the risk of nerve damage during the procedure, FDA advisory panel members recommend